1
|
Castorani V, Favalli V, Rigamonti A, Frontino G, Di Tonno R, Morotti E, Sandullo F, Scialabba F, Arrigoni F, Dionisi B, Foglino R, Morosini C, Olivieri G, Barera G, Meschi F, Bonfanti R. A comparative study using insulin pump therapy and continuous glucose monitoring in newly diagnosed very young children with type 1 diabetes: it is possible to bend the curve of HbA1c. Acta Diabetol 2023; 60:1719-1726. [PMID: 37526745 DOI: 10.1007/s00592-023-02155-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Accepted: 07/03/2023] [Indexed: 08/02/2023]
Abstract
AIMS The target of metabolic control (HbA1c < 7% or 53 mmol/mol) recommended by the ADA and ISPAD is attained by 30% of children with Type 1 Diabetes (T1D). Advances in technologies for T1D aim to improve metabolic outcomes and reduce complications. This observational study assesses the long-term outcomes of advanced technologies for treatment of T1D compared to conventional approach started at onset in a group of very young children with T1D. METHODS 54 patients with less 4 years old at onset of T1D were enrolled and followed for up to 9 years after diagnosis. 24 subjects started continuous subcutaneous insulin (CSII) treatment and 30 subjects received MDI therapy from onset. Auxological data, HbA1c and total daily insulin dose (TDD/kg) have been collected at admission and every 4 months. HbA1cAUC>6%, rates of acute complications, glycemic variability indices and glucometrics were also recorded. RESULTS Patients with CSII therapy had significantly lower mean HbA1c values compared to subjects receiving MDI treatment. CSII approach also recorded lower mean HbA1cAUC>6% and TDD/kg than MDI therapy. At the last download data, the time in range (TIR) was higher in patients with CSII and hyperglycemia events were lower. Better glycemic variability indices have been described during CSII therapy, including mean glycemia, standard deviation, coefficient of variation (CV), glycemia risk index (GRI) and high blood glucose index (HBGI). There was no statistically significant difference between frequency of severe hypoglycemia and ketoacidosis episodes between groups. CONCLUSIONS Early initiation of diabetes technologies is safe and able to determine a better long term glycemic control in young children with T1D. It also allows to flatten the trajectory of HbA1c, probably reducing microvascular, macrovascular and neurological complications of diabetes in this very peculiar age group.
Collapse
Affiliation(s)
- Valeria Castorani
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Valeria Favalli
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Andrea Rigamonti
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Giulio Frontino
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Raffaella Di Tonno
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Elisa Morotti
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Federica Sandullo
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Francesco Scialabba
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Francesca Arrigoni
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Benedetta Dionisi
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Riccardo Foglino
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Camilla Morosini
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Gabriele Olivieri
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Graziano Barera
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Franco Meschi
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy
| | - Riccardo Bonfanti
- Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy.
| |
Collapse
|
2
|
Carrera P, Marzinotto I, Bonfanti R, Massimino L, Calzavara S, Favellato Μ, Jofra T, De Giglio V, Bonura C, Stabilini A, Favalli V, Bondesan S, Cicalese MP, Laurenzi A, Caretto A, Frontino G, Rigamonti A, Molinari C, Scavini M, Sandullo F, Zapparoli E, Caridi N, Bonfiglio S, Castorani V, Ungaro F, Petrelli A, Barera G, Aiuti A, Bosi E, Battaglia M, Piemonti L, Lampasona V, Fousteri G. Genetic determinants of type 1 diabetes in individuals with weak evidence of islet autoimmunity at disease onset. Diabetologia 2023; 66:695-708. [PMID: 36692510 DOI: 10.1007/s00125-022-05865-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 10/31/2022] [Indexed: 01/25/2023]
Abstract
AIMS/HYPOTHESIS Islet autoantibodies (AAbs) are detected in >90% of individuals with clinically suspected type 1 diabetes at disease onset. A single AAb, sometimes at low titre, is often detected in some individuals, making their diagnosis uncertain. Type 1 diabetes genetic risk scores (GRS) are a useful tool for discriminating polygenic autoimmune type 1 diabetes from other types of diabetes, particularly the monogenic forms, but testing is not routinely performed in the clinic. Here, we used a type 1 diabetes GRS to screen for monogenic diabetes in individuals with weak evidence of autoimmunity, i.e. with a single AAb at disease onset. METHODS In a pilot study, we genetically screened 142 individuals with suspected type 1 diabetes, 42 of whom were AAb-negative, 27 of whom had a single AAb (single AAb-positive) and 73 of whom had multiple AAbs (multiple AAb-positive) at disease onset. Next-generation sequencing (NGS) was performed in 41 AAb-negative participants, 26 single AAb-positive participants and 60 multiple AAb-positive participants using an analysis pipeline of more than 200 diabetes-associated genes. RESULTS The type 1 diabetes GRS was significantly lower in AAb-negative individuals than in those with a single and multiple AAbs. Pathogenetic class 4/5 variants in MODY or monogenic diabetes genes were identified in 15/41 (36.6%) AAb-negative individuals, while class 3 variants of unknown significance were identified in 17/41 (41.5%). Residual C-peptide levels at diagnosis were higher in individuals with mutations compared to those without pathogenetic variants. Class 3 variants of unknown significance were found in 11/26 (42.3%) single AAb-positive individuals, and pathogenetic class 4/5 variants were present in 2/26 (7.7%) single AAb-positive individuals. No pathogenetic class 4/5 variants were identified in multiple AAb-positive individuals, but class 3 variants of unknown significance were identified in 19/60 (31.7%) patients. Several patients across the three groups had more than one class 3 variant. CONCLUSIONS/INTERPRETATION These findings provide insights into the genetic makeup of patients who show weak evidence of autoimmunity at disease onset. Absence of islet AAbs or the presence of a single AAb together with a low type 1 diabetes GRS may be indicative of a monogenic form of diabetes, and use of NGS may improve the accuracy of diagnosis.
Collapse
Affiliation(s)
- Paola Carrera
- Unit of Genomics for Human Disease Diagnosis, IRCCS Ospedale San Raffaele, Milan, Italy
- Laboratory of Clinical Molecular Biology, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Ilaria Marzinotto
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Riccardo Bonfanti
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
- Vita-Salute San Raffaele University, Milan, Italy
| | - Luca Massimino
- Department of Gastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele Hospital, Milan, Italy
| | - Silvia Calzavara
- Laboratory of Clinical Molecular Biology, IRCCS Ospedale San Raffaele, Milan, Italy
| | | | - Tatiana Jofra
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | | | - Clara Bonura
- Pediatric Department, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Angela Stabilini
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Valeria Favalli
- Pediatric Department, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Simone Bondesan
- Unit of Genomics for Human Disease Diagnosis, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Maria Pia Cicalese
- San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Andrea Laurenzi
- Department of Internal Medicine, Diabetology, Endocrinology and Metabolism, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Amelia Caretto
- Department of Internal Medicine, Diabetology, Endocrinology and Metabolism, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Giulio Frontino
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Andrea Rigamonti
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Chiara Molinari
- Department of Internal Medicine, Diabetology, Endocrinology and Metabolism, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Marina Scavini
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
- Department of Internal Medicine, Diabetology, Endocrinology and Metabolism, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Federica Sandullo
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Ettore Zapparoli
- Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Nicoletta Caridi
- Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Silvia Bonfiglio
- Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | | | - Federica Ungaro
- Department of Gastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele Hospital, Milan, Italy
| | | | - Graziano Barera
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
- Vita-Salute San Raffaele University, Milan, Italy
- Pediatric Department, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Alessandro Aiuti
- Vita-Salute San Raffaele University, Milan, Italy
- San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Emanuele Bosi
- Department of Internal Medicine, Diabetology, Endocrinology and Metabolism, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Manuela Battaglia
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
- Fondazione Telethon, Milan, Italy
| | - Lorenzo Piemonti
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
- Vita-Salute San Raffaele University, Milan, Italy
| | - Vito Lampasona
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
| | - Georgia Fousteri
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
| |
Collapse
|
3
|
Bechi Genzano C, Bezzecchi E, Carnovale D, Mandelli A, Morotti E, Castorani V, Favalli V, Stabilini A, Insalaco V, Ragogna F, Codazzi V, Scotti GM, Del Rosso S, Mazzi BA, De Pellegrin M, Giustina A, Piemonti L, Bosi E, Battaglia M, Morelli MJ, Bonfanti R, Petrelli A. Combined unsupervised and semi-automated supervised analysis of flow cytometry data reveals cellular fingerprint associated with newly diagnosed pediatric type 1 diabetes. Front Immunol 2022; 13:1026416. [PMID: 36389771 PMCID: PMC9647173 DOI: 10.3389/fimmu.2022.1026416] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 10/11/2022] [Indexed: 11/03/2023] Open
Abstract
An unbiased and replicable profiling of type 1 diabetes (T1D)-specific circulating immunome at disease onset has yet to be identified due to experimental and patient selection limitations. Multicolor flow cytometry was performed on whole blood from a pediatric cohort of 107 patients with new-onset T1D, 85 relatives of T1D patients with 0-1 islet autoantibodies (pre-T1D_LR), 58 patients with celiac disease or autoimmune thyroiditis (CD_THY) and 76 healthy controls (HC). Unsupervised clustering of flow cytometry data, validated by a semi-automated gating strategy, confirmed previous findings showing selective increase of naïve CD4 T cells and plasmacytoid DCs, and revealed a decrease in CD56brightNK cells in T1D. Furthermore, a non-selective decrease of CD3+CD56+ regulatory T cells was observed in T1D. The frequency of naïve CD4 T cells at disease onset was associated with partial remission, while it was found unaltered in the pre-symptomatic stages of the disease. Thanks to a broad cohort of pediatric individuals and the implementation of unbiased approaches for the analysis of flow cytometry data, here we determined the circulating immune fingerprint of newly diagnosed pediatric T1D and provide a reference dataset to be exploited for validation or discovery purposes to unravel the pathogenesis of T1D.
Collapse
Affiliation(s)
| | - Eugenia Bezzecchi
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
- Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Debora Carnovale
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | | | - Elisa Morotti
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
- Department of Pediatrics, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Valeria Castorani
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Valeria Favalli
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
- Department of Pediatrics, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Angela Stabilini
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Vittoria Insalaco
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Francesca Ragogna
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Valentina Codazzi
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | | | - Stefania Del Rosso
- Laboratory Medicine, Autoimmunity Section, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Benedetta Allegra Mazzi
- Immuno-Hematology and Transfusion Medicine (ITMS), IRCCS Ospedale San Raffaele, Milan, Italy
| | - Maurizio De Pellegrin
- Pediatric Orthopedic and Traumatology Unit, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Andrea Giustina
- Institute of Endocrine and Metabolic Sciences, IRCCS Ospedale San Raffaele, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Lorenzo Piemonti
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Emanuele Bosi
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
- Department of General Medicine, Diabetes and Endocrinology, IRCCS Ospedale San Raffaele, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Manuela Battaglia
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Marco J. Morelli
- Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Riccardo Bonfanti
- Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
- Department of Pediatrics, IRCCS Ospedale San Raffaele, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | | |
Collapse
|
4
|
Di Toro A, Klersy C, Giuliani L, Serio A, Disabella E, Grasso M, Smirnova A, Gambarin FI, Pasotti M, Tavazzi L, Favalli V, Arbustini E. 6128Losartan vs Nebivolol vs the association of both on the progression of aortic root dilation in genotyped Marfan Syndrome: 48 months open label randomized controlled phase III trial. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0154] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Marfan Syndrome (MFS) is a rare multisystemic genetic disease caused by mutations in the Fibrillin 1 (FBN1) gene. Aortic root aneurysm, potentially evolving to dissection and rupture, is the most important clinical complication. Beta blockers (BB) and Angiotensin II receptor blockers (ARB), these latter exerting an anti-TGFbeta1 effect, are current cornerstones of medical therapy in patients diagnosed with MFS and presenting aortic root aneurysm. The study aimed at comparing the effect of single drug (nebivolol and losartan) vs. the combination of both (losartan + nebivolol) in limiting the progression of the growth of the aortic root diameter (ARD) in FBN1 genotyped patients with aortic root aneurysm (z-score>2), who had not undergone prior aortic surgery.
Methods
We designed a controlled, open-label, single-blinded, 1:1:1 randomized, phase III single-centre study [NCT00683124]. Calculated sample size was 291 (power 90%, type I error 5%, 20% attrition, expected dropout 20%). ARD data collection was performed with annual 2D-transthoracic echocardiograms for four years. ARDs were measured with 2D-transthoracic echocardiogram as absolute values, aortic root ratio (ARR), and z-score. The primary endpoint was the modification of ARD z-score at 48 months. The analysis of the primary endpoint aimed at showing differences of ARD z-score comparing:
– The combined treatment arm (group A).
– The group aggregating both single treatment arms (group B).
– The nebivolol arm (group C).
– The losartan arm (group D).
Results
We enrolled 262 patients (126 adults, aged 17–55, and 136 children, aged 1–16); 236/262 (22 dropout; 4 lost at follow-up) completed the planned follow-up: 81 in the group A, 79 in the BB in the group C and 76 in the group D. No patient developed acute aortic dissection. Both drugs administered either individually or in combination were well tolerated without evidence of side effects. At 48 months, the ARD Z-score decreased from baseline to end-follow-up in all treatment arms. The decrease was significantly higher in the combined treatment arm (A) than in the single treatment aggregated arm (group B) with a difference in ARD z-score change of 0.17 (p=0.009) in the combined arm (A). Similarly, the decrease of z-score was inferior in the nebivolol arm and in the losartan arm than in the combined arm (by 0.16, p=0.032, and by 0.18, p=0.019, respectively). After Bonferroni correction for these post-hoc comparisons only the decrease of z-score in the losartan arm remained significantly inferior (p<0.025).
Conclusions
This study shows that the current cornerstones of medical therapy in MFS (ARB and BB) are effective in limiting the progression of the growth of the aortic root diameter: their combination exploits a synergistic effect. The combined administration of BB and ARB in patients with aortic root aneurysm is a sustainable, well tolerated treatment that effectively limits the rate of progression of aortic root dilation.
Acknowledgement/Funding
The financial support of Telethon, Italy (Grant no. GGP08238) is gratefully acknowledged.The drugs are a gift of Menarini and MSD
Collapse
Affiliation(s)
- A Di Toro
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - C Klersy
- Policlinic Foundation San Matteo IRCCS, Clinical Epidemiology and Biometry, Pavia, Italy
| | - L Giuliani
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - A Serio
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - E Disabella
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - M Grasso
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - A Smirnova
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - F I Gambarin
- Catholic University of the Sacred Heart, Department of Cardiovascular Medicine, Rome, Italy
| | - M Pasotti
- ASST Pavia-Ospedale Civile di Voghera, Cardiology Unit, Voghera, Italy
| | - L Tavazzi
- Maria Cecilia Hospital, Scientific Direction, Cotignola, Italy
| | - V Favalli
- InGenomics srl, Pavia Technopole, Pavia, Italy
| | - E Arbustini
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| |
Collapse
|
5
|
Urtis M, Smirnova A, Di Toro A, Giuliani L, Pilotto A, Di Giovannantonio M, Favalli V, Lago P, Arbustini E. P5723IEVA: Integration and Extraction of Variant Attributes in NGS analysis. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Next Generation Sequencing (NGS) technology has taken a central role in the diagnosis of genetically-determined cardiovascular diseases. The differentiation of sequencing errors from real variants is a key-point of the genetic testing. In case of novel variants or variants of uncertain significance that may potentially impact on clinical decisions (e.g. ICD implantation in primary cardiomyopathies or preventive surgery in heritable aneurysmal diseases) it is crucial to exclude false positive (FP) and false negative (FN) sequence errors. To date, Sanger Sequencing is the gold standard tool used to confirm and validate NGS-identified variants. While FPs are excluded by the Sanger confirmation and the damage is for wasted costs and time, the FNs are non-resolvable errors because they are undetected and, obviously, not searched in Sanger confirmation, with the risk of missing genetic diagnoses.
Purpose
This project aimed at reducing NGS errors through the introduction of a bioinformatic solution in the bioinformatic analytic step of the genetic testing process. iEVA is a tool that enhances NGS-derived informative features to use them in a filtering process based on a Machine Learning algorithm (ML). It considers sequencing features (e.g. technical errors, duplicates of PCR) together with nucleotide sequence characteristics.
Methods
To demonstrate the effectiveness of iEVA in eliminating FP and FN errors from the NGS bioinformatic pipeline, we developed two ML-based filtering algorithms. The training dataset consisted of 7968 single nucleotide variants (SNV) and 306 Insertions and Deletions (InDels) validated by Sanger sequencing performed by expert molecular biologists. Variants derived from 800 sequences obtained with the Illumina Trusight Cardio panel containing 174 genes related to cardiovascular diseases. Two Random Forest classifiers were trained with the task of discriminating between sequencing error and real variant. The first one was trained using attributes derived from the most common variant caller (GATK v3.8), and the second one using iEVA results. To evaluate ML models, we used a 3-Fold cross-Validation and validated the results using an independent validation dataset consisting of 3415 SNV and 132 InDels.
Results
Using iEVA attributes, we obtained 1 FP (excluded by Sanger) and 3 FN (confirmed by Sanger) less than using common variant caller attributes. In the independent validation dataset, the iEVA-trained classification model identified 1 Sanger-confirmed variant that was missed by variant caller-trained model.
Conclusions
Variant filtering is crucial to exclude sequencing errors and to recognize true variants. Even a single filtering error may negatively impact on the patient when a genetic diagnosis is missed. To obtain a certain genetic diagnosis, a 0% error probability is needed. The introduction of iEVA in the pipeline is an easy, time- and cost-saving tool to reduce errors and to improve the precision of the genetic data.
Acknowledgement/Funding
Italian Ministry of Health Research Funding to the IRCCS Foundation University Hospital Policlinico San Matteo of Pavia
Collapse
Affiliation(s)
- M Urtis
- University of Pavia, Department of Electrical, Computer and Biomedical Engineering, Pavia, Italy
| | - A Smirnova
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - A Di Toro
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - L Giuliani
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - A Pilotto
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - M Di Giovannantonio
- University of Oxford, Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, Oxford, United Kingdom
| | - V Favalli
- InGenomics srl, Pavia Technopole, Pavia, Italy
| | - P Lago
- Policlinic Foundation San Matteo IRCCS, Clinical Engeneering, Pavia, Italy
| | - E Arbustini
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| |
Collapse
|
6
|
Giuliani L, Di Toro A, Disabella E, Grasso M, Serio A, Urtis M, Pilotto A, Repetto A, Valentini A, Calliada F, Favalli V, Prati F, Arbustini E. P5539Genetic heterogeneity of spontaneous coronary artery dissection (SCAD). Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
SCAD is a rare coronary event that may cause acute coronary syndromes (ACS). SCAD predominantly occurs in apparently healthy, young to middle aged women (up to 95% of cases). The known causes include: heritable connective tissue diseases, fibromuscular dysplasia, arteritis, contraceptives, cocaine abuse and chest trauma. A variable proportion of patients manifests progression to longer segments of the same vessel or recurrence of dissection in other coronary arteries. SCAD can be the first manifestation of a previously unrecognised systemic disease.
Methods
In 2010 we started collecting consecutive SCAD, as first clinical manifestation, in patients addressed to our attention for investigation of genetic or non genetic causes, after successful management of the acute phase and exclusion of systemic inflammatory and autoimmune diseases. All patients underwent genetic visit and counselling, collection of clinical reports and imaging records, clinical cardiologic evaluation with pan-angio CT scan, biochemical testing including coagulation-related tests, and and genetic testing of genes causing connective tissue diseases. Parallel clinical family screening and genetic testing were systematically performed.
Results
The series is constituted of 35 patients (28F and 7M) (age at onset, mean ± SD, 44±7.6 years) with ACS-SCAD (20 STEMI and 15 NSTEMI) and 9 second dissections in a different coronary artery. Two sisters had ACS-SCAD caused by dissection of the same coronary artery.
We identified pathologic mutations (n=19/35, 54%) in COL3A1 (n=3), FBN1 (n=1), FBN1+TGFBR1 (n=1), TGFBR1 (n=2), TGFBR2 (n=1), MYLK (n=1), SMAD3 (n=1), COL5A1 (n=1 homozygous), COL5A2 (n=1), MYH11 (n=1), TGFB2 (n=1), ABCC6 (1 homozygous), ELN (2 homozygous sisters and 1 heterozygous unrelated patient), NOTCH1 (n=1). In 8 (23%) patients we identified VUS classified as C3 because previously unreported and predicted as uncertain on the basis of in silico analyses. In the remaining 8 patients we only identified C2 variants. A second SCAD (14 days to 78 months after the first event) occurred in 9 patients (9/35, 25%) (COL3A1 (n=2), FBN1 (n=1), FBN1+TGFBR1 (n=1), MYLK (n=1), COL5A2 (n=1), NOTCH1 (n=1) COL5A2 (n=1) and 1 with a C2 variant in COL3A1. Two patients with thrombocytosis were carriers of the somatic JAK2 V617F mutation. Extra-coronary arterial dilations/aneurysms occurred in 13 families; in the follow-up 2 patients demonstrate dissection in non-coronary arteries.
Conclusions
Our series, with the potential bias of a referral centre for inherited cardiovascular disease, demonstrated that SCAD is the possible first manifestation of a genetic disorder and that neither disease gene or mutation predicts the risk of a second coronary event. SCAD is a potentially fatal coronary event associated with ACS, warning for familial disease and unpredictable risk of recurrence.
Collapse
Affiliation(s)
- L Giuliani
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - A Di Toro
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - E Disabella
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - M Grasso
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - A Serio
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - M Urtis
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - A Pilotto
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| | - A Repetto
- Policlinic Foundation San Matteo IRCCS, Division of Cardiology, Pavia, Italy
| | - A Valentini
- Policlinic Foundation San Matteo IRCCS, Department of Radiology, Pavia, Italy
| | - F Calliada
- Policlinic Foundation San Matteo IRCCS, Department of Radiology, Pavia, Italy
| | - V Favalli
- Pavia Technopole, InGenomics srl, Pavia, Italy
| | - F Prati
- Hospital San Giovanni Addolorata, Interventional Cardiology Unit, Rome, Italy
| | - E Arbustini
- Policlinic Foundation San Matteo IRCCS, Center for Inherited Cardiovascular Diseases, Pavia, Italy
| |
Collapse
|
7
|
Lepore G, Bonfanti R, Bozzetto L, Di Blasi V, Girelli A, Grassi G, Iafusco D, Laviola L, Rabbone I, Schiaffini R, Bruttomesso D, Mammì F, Bruzzese M, Schettino M, Nuzzo M, Di Blasi V, Fresa R, Lambiase C, Iafusco D, Zanfardino A, Confetto S, Bozzetto L, Annuzzi G, Alderisio A, Riccardi G, Gentile S, Marino G, Guarino G, Zucchini S, Maltoni G, Suprani T, Graziani V, Nizzoli M, Acquati S, Cavani R, Romano S, Michelini M, Manicardi E, Bonadonna R, Dei Cas A, Dall'aglio E, Papi M, Riboni S, Manicardi V, Manicardi E, Manicardi E, Pugni V, Lasagni A, Street M, Pagliani U, Rossi C, Assaloni R, Brunato B, Tortul C, Zanette G, Li Volsi P, Zanatta M, Tonutti L, Agus S, Pellegrini M, Ceccano P, Pozzilli G, Anguissola B, Buzzetti R, Moretti C C, Leto G, Pozzilli P, Manfrini S, Maurizi A, Leotta S, Altomare M, Abbruzzese S, Carletti S, Suraci C, Filetti S, Manca Bitti M, Arcano S, Cavallo M, De Bernardinis M, Pitocco D, Caputo S, Rizzi A, Manto A, Schiaffini R, Cappa M, Benevento D, Frontoni S, Malandrucco I, Morano S, Filardi T, Lauro D, Marini M, Castaldo E, Sabato D, Tuccinardi F, Forte E, Viterbori P, Arnaldi C, Minuto N, d'Annunzio G, Corsi A, Rota R, Scaranna C, Trevisan R, Valentini U, Girelli A, Bonfadini S, Zarra E, Plebani A, Prandi E, Felappi B, Rocca A, Meneghini E, Galli P, Ruggeri P, Carrai E, Fugazza L, Baggi V, Conti D, Bosi E, Laurenzi A, Caretto A, Molinari C, Orsi E, Grancini V, Resi V, Bonfanti R, Favalli V, Bonura C, Rigamonti A, Bonomo M, Bertuzzi F, Pintaudi B, Disoteo O, Perseghin G, Perra S, Chiovato L, De Cata P, Zerbini F, Lovati E, Laneri M, Guerraggio L, Bossi A, De Mori V, Galetta M, Meloncelli I, Aiello A A, Di Vincenzo S, Nuzzi A, Fraticelli E, Ansaldi E, Battezzati M, Lombardi M, Balbo M, Lera R, Secco A, De Donno V, Cadario F, Savastio S, Ponzani C, Aimaretti G, Rabbone I, Ignaccolo G, Tinti D, Cerutti F, Bari F, Giorgino F, Piccinno E, Zecchino O, Cignarelli M, Lamacchia O, Picca G, De Cosmo S, Rauseo A, Tomaselli L, Tumminia A, Egiziano C, Scarpitta A, Maggio F, Cardella F, Roppolo R, Provenzano V, Fleres M, Scorsone A, Scatena A, Gregori G, Lucchesi S, Gadducci F, Di Cianni S, Pancani S, Del Prato S, Aragona M, Crisci I, Calianno A, Fattor B, Crazzolara D, Reinstadler P, Longhi S, Incelli G, Rauch S, Romanelli T, Orrasch M, Cauvin V, Franceschi R, Lalli C, Pianta A, Marangoni A, Aricò C, Marin N, Nogara N, Simioni N, Filippi A, Gidoni Guarneri G, Contin M.L M, Decata A, Bondesan L, Confortin L, Coracina A, Lombardi S, Costa Padova S, Cipponeri E, Scotton R, Galasso S, Boscari F, Zanon M, Vinci C, Lisato G, Gottardo L, Bonora E, Trombetta M, Negri C, Brangani C, Maffeis C, Sabbion A, Marigliano M. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion. Nutr Metab Cardiovasc Dis 2018; 28:335-342. [PMID: 29428572 DOI: 10.1016/j.numecd.2017.12.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Revised: 10/31/2017] [Accepted: 12/02/2017] [Indexed: 01/22/2023]
Abstract
BACKGROUND AND AIM The objective of this cross-sectional study was to evaluate the degree of glycaemic control and the frequency of diabetic complications in Italian people with diabetes who were treated with continuous subcutaneous insulin infusion (CSII). METHODS AND RESULTS Questionnaires investigating the organisation of diabetes care centres, individuals' clinical and metabolic features and pump technology and its management were sent to adult and paediatric diabetes centres that use CSII for treatment in Italy. Information on standard clinical variables, demographic data and acute and chronic diabetic complications was derived from local clinical management systems. The sample consisted of 6623 people with diabetes, which was obtained from 93 centres. Of them, 98.8% had type 1 diabetes mellitus, 57.2% were female, 64% used a conventional insulin pump and 36% used a sensor-augmented insulin pump. The median glycated haemoglobin (HbA1c) level was 60 mmol/mol (7.6%). The HbA1c target (i.e. <58 mmol/mol for age <18 years and <53 mmol/mol for age >18 years) was achieved in 43.4% of paediatric and 23% of adult participants. Factors such as advanced pump functions, higher rate of sensor use, pregnancy in the year before the study and longer duration of diabetes were associated with lower HbA1c levels. The most common chronic complications occurring in diabetes were retinopathy, microalbuminuria and hypertension. In the year before the study, 5% of participants reported ≥1 episode of severe hypoglycaemic (SH) episodes (SH) and 2.6% reported ≥1 episode of ketoacidosis. CONCLUSIONS Advanced personal skills and use of sensor-based pump are associated with better metabolic control outcomes in Italian people with diabetes who were treated with CSII. The reduction in SH episodes confirms the positive effect of CSII on hypoglycaemia. CLINICAL TRIAL REGISTRATION NUMBER NCT 02620917 (ClinicalTrials.gov).
Collapse
|
8
|
Gabetta M, Milani G, Bucalo M, Mulas F, Nuzzo A, Favalli V, Arbustini E, Bellazzi R, Larizza C. Supporting Translational Research on Inherited Cardiomyopathies through Information Technology. Methods Inf Med 2018; 52:137-47. [DOI: 10.3414/me12-01-0046] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2012] [Accepted: 10/05/2012] [Indexed: 12/29/2022]
Abstract
SummaryObjectives: The INHERITANCE project, funded by the European Commission, is aimed at studying genetic or inherited Dilated cardiomyopathies (DCM) and at understanding the impact and management of the disease within families that suffer from heart conditions that are caused by DCMs. The biomedical informatics research activity of the project aims at implementing information technology solutions to support the project team in the different phases of their research, in particular in genes screening prioritization and new gene-disease association discovery.Methods: In order to manage the huge quantity of scientific, clinical and patient data generated by the project several advanced biomedical informatics tools have been developed. The paper describes a layer of software instruments to support translation of the results of the project in clinical practice as well as to support the scientific discovery process. This layer includes data warehousing, intelligent querying of the phenotype data, integrated search of biological data and knowledge repositories, text mining of the relevant literature, and case based reasoning.Results: At the moment, a set of 1,394 patients and 9,784 observations has been stored into the INHERITANCE data warehouse. The literature database contains more than 1,100,000 articles retrieved from the Pubmed and generically related to cardiac diseases, already analyzed for extracting medical concepts and genes.Conclusions: After two years of project the data warehouse has been completely set up and the text mining tools for automatic literature analysis have been implemented and tested. A first prototype of the decision support tool for knowledge discovery and gene prioritization is available, but a more complete release is still under development.
Collapse
|
9
|
Narula N, Serio A, Giuliani L, Di Toro A, Giorgianni C, Poletti C, Tagliani M, Favalli V, Arbustini E. 2835Complications and management of pregnancy in Danon disease. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx495.2835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Affiliation(s)
- Giulio Frontino
- Department of Pediatrics, San Raffaele Scientific Institute , Milan, Italy
| | - Franco Meschi
- Department of Pediatrics, San Raffaele Scientific Institute , Milan, Italy
| | - Andrea Rigamonti
- Department of Pediatrics, San Raffaele Scientific Institute , Milan, Italy
| | - Valeria Favalli
- Department of Pediatrics, San Raffaele Scientific Institute , Milan, Italy
| | - Clara Bonura
- Department of Pediatrics, San Raffaele Scientific Institute , Milan, Italy
| | - Riccardo Bonfanti
- Department of Pediatrics, San Raffaele Scientific Institute , Milan, Italy
| |
Collapse
|
11
|
Frontino G, Bonfanti R, Rigamonti A, Battaglino R, Favalli V, Bonura C, Meschi F, Barera G. Management of hyperosmolar hyperglycaemic state in adults with diabetes. Diabet Med 2016. [PMID: 26206227 DOI: 10.1111/dme.12866] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- G Frontino
- Department of Pediatrics, San Raffaele Scientific Institute, Milano, Italy
| | - R Bonfanti
- Department of Pediatrics, San Raffaele Scientific Institute, Milano, Italy
| | - A Rigamonti
- Department of Pediatrics, San Raffaele Scientific Institute, Milano, Italy
| | - R Battaglino
- Department of Pediatrics, San Raffaele Scientific Institute, Milano, Italy
| | - V Favalli
- Department of Pediatrics, San Raffaele Scientific Institute, Milano, Italy
| | - C Bonura
- Department of Pediatrics, San Raffaele Scientific Institute, Milano, Italy
| | - F Meschi
- Department of Pediatrics, San Raffaele Scientific Institute, Milano, Italy
| | - G Barera
- Department of Pediatrics, San Raffaele Scientific Institute, Milano, Italy
| |
Collapse
|
12
|
Bonura C, Frontino G, Rigamonti A, Battaglino R, Favalli V, Ferro G, Rubino C, Del Barba P, Pesapane F, Nazzaro G, Gianotti R, Bonfanti R, Meschi F, Chiumello G. Necrobiosis Lipoidica Diabeticorum: A pediatric case report. Dermatoendocrinol 2014; 6:e27790. [PMID: 24575162 PMCID: PMC3917223 DOI: 10.4161/derm.27790] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/25/2013] [Accepted: 01/09/2014] [Indexed: 11/19/2022]
Abstract
Introduction: Necrobiosis lipoidica (NL) is a rare chronic granulomatous dermatitis that usually appears in the lower extremities. It affects about 0.3–1.2% of diabetic patients, the majority of whom have type 1 diabetes. The etiology and pathogenesis of this disorder are still unclear. NL is characterized by skin rash that usually affects the shins. The average onset is 30 years, with females being affected more commonly. There are very few reported cases of necrobiosis lipoidica in children.
Case report: We report a case of a 16 year old girl affected by type 1 diabetes mellitus (15 years disease duration) who developed an erythematous nodular rash on the lower extremities and interscapular area. In the suspect of necrobiosis lipoidica, a skin biopsy was performed (lower extremities and interscapular area). The microscopic evaluation of the pretibial lesions was suggestive of necrobiosis lipoidica. The smaller lesions in the interscapular area showed signs of perivascular dermatitis which could be consistent with early stages of necrobiosis lipoidica. Local treatment with tacrolimus determined a progressive improvement of the lesions.
Conclusion: In patients with T1DM, diagnosis of NL of the lower legs is usually unequivocal. However, diagnosis may be more challenging in the presence of lesions with recent onset and/or atypical clinical presentation and unusual site. In these cases, NL must always be taken in consideration in order to avoid misdiagnosis, wrong/late treatment decisions and progression to ulceration.
Collapse
Affiliation(s)
- Clara Bonura
- Ospedale San Raffaele Scientific Institute; Department of Pediatrics; Milano, Italy
| | - Giulio Frontino
- Ospedale San Raffaele Scientific Institute; Department of Pediatrics; Milano, Italy
| | - Andrea Rigamonti
- Ospedale San Raffaele Scientific Institute; Department of Pediatrics; Milano, Italy
| | - Roseila Battaglino
- Ospedale San Raffaele Scientific Institute; Department of Pediatrics; Milano, Italy
| | - Valeria Favalli
- Ospedale San Raffaele Scientific Institute; Department of Pediatrics; Milano, Italy
| | - Giusy Ferro
- Ospedale San Raffaele Scientific Institute; Department of Pediatrics; Milano, Italy
| | - Chiara Rubino
- Ospedale San Raffaele Scientific Institute; Department of Pediatrics; Milano, Italy
| | - Paolo Del Barba
- Ospedale San Raffaele Scientific Institute; Department of Pediatrics; Milano, Italy
| | - Filippo Pesapane
- Università degli Studi di Milano; Fondazione IRCCS Ca' Granda Osp. Maggiore Policlinico; Department of Pathophysiology and Transplantation; Milano, Italy
| | - Gianluca Nazzaro
- Università degli Studi di Milano; Fondazione IRCCS Ca' Granda Osp. Maggiore Policlinico; Department of Pathophysiology and Transplantation; Milano, Italy
| | - Raffaele Gianotti
- Università degli Studi di Milano; Fondazione IRCCS Ca' Granda Osp. Maggiore Policlinico; Department of Pathophysiology and Transplantation; Milano, Italy
| | - Riccardo Bonfanti
- Ospedale San Raffaele Scientific Institute; Department of Pediatrics; Milano, Italy
| | - Franco Meschi
- Ospedale San Raffaele Scientific Institute; Department of Pediatrics; Milano, Italy
| | - Giuseppe Chiumello
- Ospedale San Raffaele Scientific Institute; Department of Pediatrics; Milano, Italy
| |
Collapse
|
13
|
Grasso V, Colombo C, Favalli V, Galderisi A, Rabbone I, Gombos S, Bonora E, Massa O, Meschi F, Cerutti F, Iafusco D, Bonfanti R, Monciotti C, Barbetti F. Six cases with severe insulin resistance (SIR) associated with mutations of insulin receptor: Is a Bartter-like syndrome a feature of congenital SIR? Acta Diabetol 2013; 50:951-7. [PMID: 23824322 DOI: 10.1007/s00592-013-0490-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2013] [Accepted: 06/08/2013] [Indexed: 10/26/2022]
Abstract
Biallelic insulin receptor (INSR) gene mutations cause congenital syndromes of severe insulin resistance (SIR) known as Donohue syndrome (DS) and Rabson-Mendenhall syndrome (RMS). At presentation, DS and RMS are difficult to differentiate since they share many clinical features; however, while patients with DS usually die within 1 year of birth, individuals classified as RMS can reach adult age. INSR mutations can be also found in pubertal females with hyperinsulinism, hyperandrogenism, and acanthosis nigricans (type A SIR). We studied the INSR gene in five subjects with congenital SIR and in a patient with type A SIR. Nine biallelic INSR gene mutations (eight novels, including an in-frame deletion of INSR signal peptide) were identified in patients with congenital SIR; a heterozygous, spontaneous INSR mutation was detected in the patient with type A SIR. Two probands, presenting severe hirsutism at birth, died at the age of 3 months and were classified as DS, while other 2, currently 2 and 3 years old, were diagnosed with RMS (patients 3 and 4). The fifth patient with congenital SIR died when 14 months old. Nephrocalcinosis, hyperaldosteronism, hyperreninemia, and hypokalemia, in the absence of hypertension, were discovered in patients 3 and 5 when 24 and 4 months old, respectively. Patient 3, now 3 years/3 months old, still shows hyperreninemic hyperaldosteronism requiring potassium supplementation. We conclude that renal abnormalities resembling antenatal Bartter's syndrome type II, recently reported also by others, is a common observation in patients with congenital SIR.
Collapse
Affiliation(s)
- Valeria Grasso
- Laboratory of Mendelian Diabetes, Bambino Gesù Childrens' Hospital, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Frontino G, Meschi F, Bonfanti R, Rigamonti A, Battaglino R, Favalli V, Bonura C, Ferro G, Chiumello G. Future Perspectives in Glucose Monitoring Sensors. Eur Endocrinol 2013; 9:6-11. [PMID: 30349603 DOI: 10.17925/ee.2013.09.01.21] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2013] [Accepted: 02/14/2013] [Indexed: 11/24/2022]
Abstract
The prevalence of diabetes is increasing. improved glucose control is fundamental to reduce both long-term micro- and macrovascular complications and short-term complications, such as diabetic ketoacidosis and severe hypoglycemia. Frequent blood glucose monitoring is an essential part of diabetes management. However, almost all available blood glucose monitoring devices are invasive. This determines a reduced patient compliance, which in turn reflects negatively on glucose control. Therefore, there is a need to develop noninvasive glucose monitoring devices that will reduce the need of invasive procedures, thus increasing patient compliance and consequently improving quality of life and health of patients with diabetes.
Collapse
Affiliation(s)
- Giulio Frontino
- Department of Pediatrics, San Raffaele Scientific Institute, Milan, Italy
| | - Franco Meschi
- Department of Pediatrics, San Raffaele Scientific Institute, Milan, Italy
| | - Riccardo Bonfanti
- Department of Pediatrics, San Raffaele Scientific Institute, Milan, Italy
| | - Andrea Rigamonti
- Department of Pediatrics, San Raffaele Scientific Institute, Milan, Italy
| | - Roseila Battaglino
- Department of Pediatrics, San Raffaele Scientific Institute, Milan, Italy
| | - Valeria Favalli
- Department of Pediatrics, San Raffaele Scientific Institute, Milan, Italy
| | - Clara Bonura
- Department of Pediatrics, San Raffaele Scientific Institute, Milan, Italy
| | - Giusy Ferro
- Department of Pediatrics, San Raffaele Scientific Institute, Milan, Italy
| | - Giuseppe Chiumello
- Department of Pediatrics, San Raffaele Scientific Institute, Milan, Italy
| |
Collapse
|
15
|
Frontino G, Meschi F, Bonfanti R, Rigamonti A, Battaglino R, Favalli V, Bonura C, Ferro G, Chiumello G. Future Perspectives in Glucose Monitoring Sensors. ACTA ACUST UNITED AC 2013. [DOI: 10.17925/use.2013.09.01.21] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The prevalence of diabetes is increasing. Improved glucose control is fundamental to reduce both long-term micro- and macrovascular complications and short-term complications, such as diabetic ketoacidosis and severe hypoglycemia. Frequent blood glucose monitoring is an essential part of diabetes management. However, almost all available blood glucose monitoring devices are invasive. This determines a reduced patient compliance, which in turn reflects negatively on glucose control. Therefore, there is a need to develop noninvasive glucose monitoring devices that will reduce the need of invasive procedures, thus increasing patient compliance and consequently improving quality of life and health of patients with diabetes.
Collapse
|
16
|
Frontino G, Bonfanti R, Scaramuzza A, Rabbone I, Meschi F, Rigamonti A, Battaglino R, Favalli V, Bonura C, Sicignano S, Gioia E, Zuccotti GV, Cerutti F, Chiumello G. Sensor-augmented pump therapy in very young children with type 1 diabetes: an efficacy and feasibility observational study. Diabetes Technol Ther 2012; 14:762-4. [PMID: 22694194 DOI: 10.1089/dia.2012.0044] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND Efficacy and feasibility of sensor-augmented pump (SAP) therapy were evaluated in very young children with type 1 diabetes (T1D). SUBJECTS AND METHODS SAP (Dexcom [San Diego, CA] Seven Plus™ usage combined with insulin pump) therapy was retrospectively evaluated in 28 children (15 boys) younger than 7 years (mean age, 5.8 ± 1.2 years; range, 3-7 years), with T1D. Glycosylated hemoglobin (HbA1c) was evaluated at baseline and at the end of the study, as were efficacy and feasibility of the system, using a rating scale (with 3 being the most positive). RESULTS SAP has been used for at least 6 months by 85% of patients, with an overall good satisfaction (92%). The greatest perceived benefit was the reduced fear of hypoglycemia (score of 3, 81%). HbA1c significantly improved only in patients with baseline HbA1c >7.5% (P = 0.026). CONCLUSIONS SAP therapy is effective and feasible in preschool children with T1D. In patients with high HbA1c at baseline it provide a 0.9% decrease, sustained for at least 6 months.
Collapse
Affiliation(s)
- Giulio Frontino
- Department of Pediatrics, Endocrine Unit, Scientific Institute Hospital San Raffaele, Vita-Salute University, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Favalli V, Bonfanti R, Meschi F, Viscardi M, Rigamonti A, Biffi V, Frontino G, Battaglino R, Bonura C, Chiumello G. Long term efficacy of insulin pump therapy in preschool children with diabetes. Pediatr Med Chir 2012; 34:129-32. [DOI: 10.4081/pmc.2012.78] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
18
|
Battaglino R, Bonfanti R, Favalli V, Viscardi M, Meschi F, Chiumello G. [Glucose monitoring in children with type 1 diabetes mellitus. New insights]. Pediatr Med Chir 2011; 33:217-220. [PMID: 22428429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023] Open
Affiliation(s)
- R Battaglino
- Unitá funzionale di diabetologia pediatrica, Clinica Pediatrica istituto Scientifico San Raffaele, Milano, Italia.
| | | | | | | | | | | |
Collapse
|